Schmackofatz

Subsequent purchase of $NOVO B (-0,1 %)

position full for the time being.

...are you running through regardless of the market situation?

To the screenshot still runs weekly 25€ $BTC (+1,68 %) on Bison. I might still throw $NOVO B (-0,1 %) in, currently down 18% or so 😭

Imagine you own shares in a company - let's say 100 shares in Apple. You believe that the share price will tend to move sideways in the near future. Instead of simply holding on, you can generate extra income with covered calls.

This is how it works:

- You own the shares (hence "covered").

- You sell a call option on these shares. This gives someone else the right to buy your shares at a certain price (strike) up to a certain date.

- You receive a premium for this sale - and that is your income.

What can happen?

1. the price remains below the strike:

=> Nobody exercises the option, you keep your shares and the premium. Win!

2. price rises above the strike:

=> Your shares are "taken", you have to sell them at the strike. You receive less than the current market price, but you keep the premium.

What is this good for?

- Additional income in sideways markets.

- Some risk protection through the premium.

The risks?

- Limited profit potential (because you have to sell the shares if they rise sharply).

- If the share falls sharply, the premium only protects you a little - you still bear the price risk.

In short: covered calls are like rental income for your shares - you give up profits but collect regular premiums (dividends, etc.).

$SPYI
$QQQI
$QYLE (+0,03 %)
$AAPL (-0,04 %)
$MSFT (+0,9 %)
$AMZN (+0,48 %)
$GOOGL (+1,06 %)
$RHM (+2,24 %)
$NVDA (+0,32 %)
$NOVO B (-0,1 %)
$O (-0,56 %)
$NKE (+0,31 %)
$TSLA (+2,54 %)

SAP overtakes Novo Nordisk as the most valuable company in Europe

The SAP share $SAP (+0,3 %) shares are currently showing an impressive upward trend. In an exciting race, the technology group from Walldorf has overtaken Novo Nordisk $NOVO B (-0,1 %) and thus secured the title of the most valuable company in Europe. With a market capitalization of 314 billion euros, SAP has overtaken the Danish company, whose value has fallen to around 310 billion euros. This remarkable change is the result of a successful recovery in SAP shares, which have benefited greatly from the company's innovative cloud strategy. This strategy marks a turning point: instead of just selling software licenses, SAP now offers a form of rental via the cloud that is more flexible and appealing to customers. In addition, the boom in the field of artificial intelligence has significantly supported the positive development. In contrast, Novo Nordisk shares have suffered a dramatic fall of almost 50% since their record high last June, due to increasing competition in the lucrative field of weight loss drugs.

Trump threatens new tariffs on oil from Russia

President Trump is causing a stir in the US by announcing a series of tariffs that could have a fundamental impact on trade. On Wednesday, he unveiled the introduction of 25% tariffs on all foreign vehicles, to come into force from April 2. Trump referred to this day as "Liberation Day" and hinted that other trade agreements could also be on the brink. Particularly alarming is his threat to impose 25% tariffs on oil and gas from Venezuela, which could not only strain US trade relations with several countries but also destabilize global energy markets. The EU has already responded with countermeasures to the previously introduced tariffs on steel and aluminum. Trump emphasizes that the tariffs should be fair and pleasant for other countries, but at the same time he hints that higher tariffs are on the cards if other countries try to harm the US economically.

Sources:

https://www.n-tv.de/wirtschaft/SAP-ist-jetzt-Europas-wertvollstes-Unternehmen-article25651782.html

https://finance.yahoo.com/news/live/trump-tariffs-live-updates-trump-threatens-oil-tariffs-on-russia-scholz-says-eu-prepared-to-respond-to-steel-aluminum-levies-191201517.html

I am 18 years old and started investing last October.

I have a part-time job with an income of €350 a month.

I need this for my savings plan on

$NOVO B (-0,1 %)
$NKE (+0,31 %)
$SOFI (+1,15 %)
$CSNDX (+0,3 %)
$QBTS (-0,53 %) and $1211 (-2,63 %)

I follow the dividend strategy, but I also have a few non-dividend stocks in it because I think they have potential with an investment horizon of at least 10 years.

How would you rate my portfolio?

What is your opinion on Avance Gas?

Best regards and thank you very much for your feedback - it is very important to me!

The price/earnings ratio (P/E ratio) shows how expensive a share is in relation to its earnings.

Formula: Share price / earnings per share

Example:

Share price €100, earnings per share = €5 → P/E ratio = 20

A high P/E ratio can indicate growth - or overvaluation.

A low P/E ratio looks favorable - but can also be a warning signal.

Conclusion: P/E ratio is a useful tool, but not an oracle. Always look at it in context!

How important is the P/E ratio for your investments?

$AAPL (-0,04 %)
$NVDA (+0,32 %)
$TSLA (+2,54 %)
$MSFT (+0,9 %)
$NOVO B (-0,1 %)
$AMZN (+0,48 %)
$GOOGL (+1,06 %)
$RHM (+2,24 %)
$NKE (+0,31 %)
$ASML (+0,11 %)
$AMD (+0,16 %)

The year to date shows that excessive dependency harbors risks. Increasing political uncertainty and high valuations are prompting many investors to look for alternatives. Europe and Asia offer exciting companies that are often valued more favorably and have great long-term potential.

Strong European alternatives for your portfolio:

Adyen $ADYEN (-0,47 %) is a leading payment service provider that is benefiting from increasing digitalization. After a difficult year, the company could get back on track.

Schneider Electric $SU (+1,1 %) from France is a key player in energy and automation technology and is benefiting from electrification and the growing focus on sustainability.

Novo Nordisk $NOVO B (-0,1 %) a classic and dominates the market for diabetes and obesity medication. The strong demand for Wegovy and Co. ensures continuous growth.

ASML $ASML (+0,11 %) is indispensable for the chip industry. Without ASML's machines, there would be no modern semiconductors. A real growth stock for the future.

Lotus Bakeries $LOTB (+0,67 %) is growing worldwide with its popular Biscoff cookies. The expansion into new markets makes the company exciting for long-term investors. More on this in one of my last posts.

Exciting stocks from Asia:

Tokyo Electron $8035 (+0,53 %) is one of the most important suppliers to the semiconductor industry and is benefiting from the global chip boom.

Alibaba $9988 (+0,69 %) remains an e-commerce and cloud giant with long-term potential despite regulatory challenges.

Fast Retailing $9983 (-0,44 %) (Uniqlo) is growing strongly in Asia and could establish itself as a global fashion brand.

The MSCI World ex USA as an alternative for passive investors:

If you want to reduce your US share but do not want to invest in individual stocks, you can use an ETF on the MSCI World ex USA as an alternative. Regular purchases via a savings plan can gradually dilute the US share in the portfolio.

What is your current US share? Are you planning to reallocate or are you still heavily invested in the USA?

#etfs
#stockanalysis
#tech
#dividends
#growth
#usa
#eu
#asien

Peter Lynch was a star investor. When he retired in 1990, his fund assets had grown to 14 billion US dollars. Here are his five golden rules of success.

Hello my dears,

Can we learn anything from Peter Lynch's rules?

- Buy and hold strategy means a lot of discipline in these turbulent times.

Don't rush and keep calm.

- Invest in what you know and understand.

Even in a correction and bear market, it helps us to continue to believe in the company. And to hold on to the share. The same applies if we know the fundamental figures and know that a company will continue to operate successfully.

- I find the statement interesting:

"Companies are allowed to grow, but only at a pace that is sustainable in the long term. It excludes companies that grow too quickly.

I think this certainly includes hype stocks.

I often see great opportunities in such shares, but Lynch's statement also makes me think. Because you can see it in companies such as

- Elf Beauty $ELF (+4,54 %)

Here the share price rose rapidly when the company was growing at triple-digit rates. Now that the company is only growing in double digits. Investors are suddenly no longer satisfied. And a high P/E ratio is no longer acceptable. As you can see from the chart.

Maybe you can see it with Nvidia $NVDA (+0,32 %) Tesla $TSLA (+2,54 %) or $NOVO B (-0,1 %) similar developments? Because growth is slowing here. Or are they buy and hold stocks for you? Or what would be your current Peter Lynch shares?

Summarized for you

Invest in what you know and understand.

Apply a long-term buy-and-hold strategy.

Five rules: Growth, valuation, liquidity, profitability.

"Invest in what you know and understand". This is the famous saying of star investor and fund manager Peter Lynch.

In his book "One Up on Wall Street", he describes the principles of his investment strategy

Lynch's investment strategy is based on fundamental analysis and follows a long-term buy-and-hold strategy. It focuses on finding growing companies with reasonable to low valuations. Although this strategy contains some elements of growth investing, it leans more towards a value investing approach.

Pure growth investing strategies often include a technical analysis and market timing component. Lynch, however, does not use these. He recommends ignoring market volatility and focusing solely on building a long-term diversified portfolio that takes into account a company's valuation, profitability and overall financial health.

Companies are allowed to grow, but only at a pace that is sustainable in the long term. It excludes groups that grow too quickly.

Does that work? Well, it has certainly worked for him:

As manager of the Magellan Fund, Lynch achieved an average annual return of 29.2 percent between 1977 and 1990. That is almost three times the average annual return of the S&P 500.

According to Lynch, many good investment ideas can come from things you use, like or buy in your daily life. In line with the credo: "Invest in what you know and understand"

The company doesn't have to be in the next hot or growing area, but simply offer goods or services that are valued in their particular field. Companies can also be active in relatively boring areas. In fact, the more boring and understandable, the better.

The next step is to research the company. Before you actually buy, you need to do your homework and make sure you understand the company's business.

After buying shares in a company, the next step is patience. Lynch explained that you can't make a reasonable prediction about the price of the company or the market over the next 1 or 2 years, but over 10 or 20 years the price is more predictable. A portfolio of 10 to 30 well selected and diversified stocks should perform well over 10 to 20 years.

Lynch's investment rules

First rule: Earnings per share should have grown by at least 15 percent on average over the last 5 years. This growth should not exceed 30 percent, as such growth is not sustainable. In your research, it will be important to understand how and why this growth was achieved and to assess whether similar growth can be sustained in the future.

Second rule: The PEG (Price-to-Earnings Growth) ratio should be less than 1. The PEG ratio takes into account the P/E ratio. The PEG ratio is calculated by dividing the P/E ratio by the company's annual earnings growth (usually for the next 5 years).

Third rule: Pay attention to the debt/equity ratio. This ratio is a financial indicator that measures the ratio of debt capital (debt) to a company's equity. It is calculated by dividing the debt capital by the equity capital. This should not result in a value of more than 0.6.

Fourth rule: The current ratio (also known as the liquidity ratio) is a business ratio that measures a company's ability to cover its current liabilities with its current assets. It is calculated by dividing the current assets (i.e. all assets that can be converted into cash within one year) by the current liabilities (i.e. all liabilities that fall due within one year). The value should not be greater than 1.

Fifth rule: Pay attention to the ROE (return on equity). It measures the profitability of a company in relation to its equity. An ROE > 15 percent means that the company achieves a return of more than 15 percent on the equity invested. ROE is calculated by dividing a company's net profit by its equity.

Author: Krischan Orth, wallstreetONLINE editorial team.

https://www.wallstreet-online.de/nachricht/19165555-investieren-profi-peter-lynch-goldenen-regeln-erfolgreiches-investment

$SAN (-0,12 %)
$NOVO B (-0,1 %)
$PFE (-0,43 %)

The US Food and Drug Administration (FDA) approved Sanofi's hemophilia therapy on Friday. This paves the way for a treatment method for patients with rare blood clotting disorders. The therapy, which is marketed under the name Qfitlia, is new to the spectrum. However, Novo Nordsik and Pfizer are also active in this market.

Qfitlia is a therapy that is administered under the skin. It is intended to help prevent bleeding and reduce antithrombin levels. Qfitlia is approved for haemophilia patients aged 12 and over. According to estimates by the National Hemophilia Foundation, there are 30,000 to 33,000 haemophilia patients in the USA and around one million people worldwide are affected by the disease.

According to Reuters, the newly approved therapy is the first in its class to lower antithrombin levels and is suitable for people with haemophilia A or B with or without inhibitors.

Compared to the already approved therapies from Novo Nordisk and Pfizer, the Sanofi therapy has to be administered much less frequently, which makes treatment easier. Specifically, Qfitlia will only need to be administered every two months, while treatments with Pfizer's Hympavzi injection need to be administered weekly and Novo Nordisk's Alhemo even daily.

"Today's approval of Qfitlia is a significant step forward for hemophilia patients, as the therapy needs to be administered less frequently than other existing options," said FDA member Tanya Wroblewski as part of the approval decision.

https://www.deraktionaer.de/artikel/aktien/sanofi-fda-gibt-gruenes-licht-so-reagieren-die-aktien-der-rivalen--20377529.html